» Articles » PMID: 36209521

Nucleolin Expression Has Prognostic Value in Neuroblastoma Patients

Abstract

Background: Neuroblastoma (NB) represents the most frequent form of extra-cranial solid tumour of infants, responsible for 15% of childhood cancer deaths. Nucleolin (NCL) prognostic value in NB was investigated.

Methods: NCL protein expression was retrospectively evaluated in tumour samples of NB patients at diagnosis and after chemotherapy. NCL prognostic value at mRNA level was assessed in a cohort of 20 patients with stage 4 NB (qPCR20, n=20, discovery dataset) and in the MultiPlatform786 including 786 patients of all stages (validation dataset). Overall and event-free survival curves were plotted by Kaplan-Meier method and compared by log-rank test.

Findings: NCL protein, down-modulated after chemotherapy in association with features of neuroblastic differentiation,resulted statistically significantly overexpressed in NB tumours and higher in stage 4 compared to stage 1,2,3 patients. In the stage 4 patients cohort qPCR20, patients with high NCLmRNA expression revealed a statisticallysignificant lower survival probability than those with low NCL expression (OS: HR 4.1 95%CI 1.2-13.8;p=0.0215[Log-rank test], EFS: HR 4.1 95%CI 1.2-14.0, p=0.0197[Log-rank test]). In the MultiPlatform786 (n=786), multivariate analysis suggested thatNCL expression has a statistically significant prognostic value even in the model adjusted for established prognostic markers. NCL expression significantly stratified also patients with >18 months and stage 4 tumour (OS: HR 1.8 95%CI 1.2-2.7, p=0.0009[Log-rank test]; EFS: HR 1.7 95%CI 1.1-2.5, p=0.002[Log-rank test]), patients with>18 months stage 4 with MYCN non amplified tumour[EFS: HR 2.3 95%CI 1.2-4.7, p=0.01[Log-rank test]), and patients with MYCN non amplified and MYC high [OS: HR 11.9 95%CI 2.3-62.4, p=0.003[Log-rank test]; EFS: HR 7.2 95%CI 1.6-33.4, p=0.01[Log-rank test]). A statistically significant correlation between NCL and MYCN, MYC, and TERT was found in independent datasets (MultiPlatform786 (n=786) and Agilent394 (n=394). Gene set enrichment analysis revealed a statisticallysignificant positive enrichment of MYC target genes and genes involved in telomerase maintenance.

Interpretation: NCL is a novel and independent (adjusting for age, INSS stage, and MYCN status) prognostic marker for NB.

Funding: IMH-EuroNanoMed II-2015 and AIRC-IG.

Citing Articles

RNA Sequencing and Weighted Gene Co-Expression Network Analysis Highlight DNA Replication and Key Genes in Nucleolin-Depleted Hepatoblastoma Cells.

Steinkellner H, Madritsch S, Kluge M, Seipel T, Sarne V, Huber A Genes (Basel). 2025; 15(12.

PMID: 39766782 PMC: 11675179. DOI: 10.3390/genes15121514.


Asymmetric distribution of G-quadruplex forming sequences in genomes of retroviruses.

Kledus F, Dobrovolna M, Mergny J, Brazda V Sci Rep. 2025; 15(1):76.

PMID: 39747944 PMC: 11696869. DOI: 10.1038/s41598-024-82613-2.


Integrated Multiomics Reveals Silencing of has_circ_0006646 Promotes TRIM21-Mediated NCL Ubiquitination to Inhibit Hepatocellular Carcinoma Metastasis.

Hu X, Chen G, Huang Y, Cheng Q, Zhuo J, Su R Adv Sci (Weinh). 2024; 11(16):e2306915.

PMID: 38357830 PMC: 11040345. DOI: 10.1002/advs.202306915.


Plasma-Derived Exosome Proteins as Novel Diagnostic and Prognostic Biomarkers in Neuroblastoma Patients.

Morini M, Raggi F, Bartolucci M, Petretto A, Ardito M, Rossi C Cells. 2023; 12(21).

PMID: 37947594 PMC: 10649754. DOI: 10.3390/cells12212516.


A novel nomogram for predicting post-recurrence survival in recurrent neuroblastoma patients.

Chen W, Fang Y, Lin P, Bai J, Fang Y, Zhang B Am J Cancer Res. 2023; 13(6):2254-2268.

PMID: 37424797 PMC: 10326575.